Eloralintide vs Survodutide | GLP-1R/GCGR vs Dual GLP-1/GCGR | QSC
Eloralintide vs Survodutide
GLP-1R/GCGR Dual Agonist vs Dual GLP-1/GCGR — Mechanism, Data & Research Application Comparison | QSC
Factor
Eloralintide
Survodutide
Class
Dual GLP-1R/GCGR Agonist
Dual GLP-1/GCGR
Mechanism
GLP-1R + GCGR co-agonism
GLP-1R+GCGR dual agonist
Best Trial Result
~10–11% wt loss · ~40–50% liver fat ↓
~15% (Phase 2)
NASH / Liver Data
✓ Phase 2 — direct GCGR/CPT1A
Phase 2 NASH positive
GCGR Component
✓ Direct hepatic fat oxidation
✓
At QSC
✓ In stock — first mover
✓ In stock
Research Analysis: Same receptor class — both are GLP-1R/GCGR dual agonists — but different molecules with different GCGR/GLP-1R agonism ratios and structural sequences. Survodutide (BI 456906, Boehringer Ingelheim) shows ~15% weight loss vs eloralintide’s ~10–11%, suggesting a higher effective GCGR or GLP-1R agonism ratio. Both have Phase 2 NASH data. Researchers can use both from QSC for comparative GLP-1R/GCGR pharmacology within the same receptor class — comparing two structurally distinct molecules with the same target combination.
What is the difference between eloralintide and Survodutide?
Eloralintide is a dual GLP-1R/GCGR co-agonist; Survodutide is a Dual GLP-1/GCGR. The key mechanistic difference is the presence or absence of GCGR: eloralintide’s GCGR agonism drives direct hepatic CPT1A-mediated fat oxidation — independent of body weight loss. Same receptor class — both are GLP-1R/GCGR dual agonists — but different molecules with different GCGR/GLP-1R agonism ratios and structural sequences. Survodutide (BI 456906, Boehringer Ingelheim) shows ~15% weight loss vs eloralintide’s ~10–11%, sug
Which is better for NASH research: eloralintide or Survodutide?
For research specifically targeting direct hepatic fat oxidation via GCGR/CPT1A, eloralintide is the dedicated tool — Phase 2 data shows ~40–50% liver fat reduction, disproportionate to ~10–11% weight loss. Both compounds have direct GCGR mechanisms for comparison.
Are both eloralintide and Survodutide available at QSC?
Yes — both eloralintide and Survodutide are available at QSC (qscpeptide.com) at ≥99% HPLC purity with Janoshik independent COA verification. US Domestic Warehouse, 2–4 business day delivery. Researchers can source both compounds from one verified supplier for comparative protocols.
Research Use Only: Eloralintide is sold by QSC strictly for in vitro laboratory research purposes only. Not for human or veterinary use. Not FDA approved for clinical use.
